SCROLL
SCROLL
Our promise
We believe in the power of our path — as meaningful as its manifestation.
We want to make visible what lies underneath our efforts, to demonstrate how the progress of oncology care starts from here.
We exist to push humanity forward.
Oncology forward.
Whatever it takes.
People
A community of ambitious people of science.
“Our most precious resources are the scientists. We want to get on the top of the game again – also for them.”
History
A glorious past, embraced with resilience.
“When I remember Nerviano’s golden age with the people that worked there, I always hear them say when we were warriors.”
Location
A place, around which
everyone is tied to.
“Companies come and go, but scientists have been doing research here since ’60s.”
About us
Research and development of personalized therapies for cancer patients
We have a mission. To improve patients’ health through our unwavering commitment to discover, develop and deliver life-changing molecules.
Every day we discover, develop, and create new molecules and new personalized oncology therapeutic strategies to improve the lives of people suffering from cancer.
NMS Group is the largest company in Italy committed to oncology innovation and the only institution able to manage the entire integrated R&D chain: from the first steps of the pre-clinical phase to the packaging of the finished product, thanks to the Group’s subsidiaries that each excels in its field.
Perseverance, Respect, Integrity, Dedication and Empathy, we PRIDE our values.
The international certifications, the continuous interactions with public and private scientific institutions and the strong network of collaborations with the scientific community and other industries are the guarantee of our excellence.
NMS Group
Over 50 years, NMS Group has been an important international benchmark, in the sector of personalized therapy in oncology. NMS Group, headquartered in Nerviano (MI), and one of the largest companies committed to innovation, research, and development in oncology, has more than 400 employees and 3 shareholding companies, each with its own specialization.
This allows us to guarantee the best at every step of the process: from the research of new molecular targets to preclinical trails, clinical trials, commercial manufactory to packaging of innovative drugs, up to regulatory approvals in various countries and patents granted all over the globe.
DISCOVER MORE
The Group’s subsidiaries are: Nerviano Medical Sciences, Accelera and NerPharMa.
Nerviano Medical
Sciences
Nerviano MS represents the innovative core of our Group and is engaged in the discovery and development of new oncology drugs. Each day, our 130 researchers seek and develop new targeted therapy opportunities to generate highly effective and selective molecules.
DISCOVER MORE
Accelera
Accelera is one of the few Italian companies committed to preclinical research and experimentation. It offers integrated high level services for biotech and pharmaceutical companies, as well as academic Institutes and non-profit organizations at a global level.
DISCOVER MORE
NerPharMa
Nerpharma deals with the development and manufacturing of products, beginning with the formulation of the active ingredient up to packaging, from the management of the clinical distribution chain to the regulatory approvals in the different countries.
DISCOVER MORE
Latest News & Events
Visit Accelera Team at the SOT 2023 Annual Meeting in Nashville, Tennessee (March 19-23)
Visit Accelera Team
at the SOT 2023 Annual Meeting in Nashville, Tennessee
March 19 – 23
Booth #1214
Visit our booth for an overview of our services
(Click the title for the complete article)
Nerviano Medical Sciences Appointed Anders Elm Pedersen, MD, PhD, DMSc, as Senior Medical Director to accelerate further the Global Clinical Development progress
NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead the clinical strategy and clinical development plans of the Company’s ever-growing pipeline. Anders brings extensive research, clinical development and medical affairs experience to NMS, and authored more than 80 research publications within preclinical and clinical research .
(Click the title for the complete article)
Accelera sponsor del 21° congresso nazionale SITOX – Bologna (20-22 Febbraio 2023)
Accelera è Sponsor del 21° congresso nazionale SITOX che si svolgerà a Bologna il giorno 21 febbraio (dalle 11.00 alle 12.00), presenterà il poster “Valutazione preclinica della tossicità a carico del SNC nel soggetto pediatrico: tecniche istologiche in neonati di ratto”.
nella sessione P3 Farmaci
Numero del poster: P3/1
(Click the title for the complete article)
Latest Events
Latest News
Welcome and Check out our new motion picture!